Detailed Analysis of United States Patent 6,143,775: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,143,775?
United States Patent 6,143,775 covers the composition and method of using a specific drug candidate. Filed on August 24, 1999, and issued on November 7, 2000, the patent claims a novel class of compounds with therapeutic applications.
Composition and structural claims
The patent claims a novel chemical compound characterized by a specific molecular structure. The core of the invention involves a substituted heterocyclic compound with particular functional groups at designated positions.
Structural elements:
- Heterocyclic core: A pyrimidine ring
- Substituents: An amino group at position 4, and a phenyl group at position 2
- Additional functional groups: Methyl and halogen substitutions at specific positions
Method claims
The patent claims methods of using the compounds for treating specific diseases, including viral infections and inflammatory disorders. The claimed methods involve administering the compound in a therapeutically effective dose.
Scope implications
The patent covers both the chemical structure and its therapeutic application, with a breadth that extends to all derivatives and analogs explicitly or implicitly included by the structural definitions.
How do the claims define patent protection?
Independent claims
The patent features three independent claims:
- Claim 1: A chemical compound with a pyrimidine core substituted as described.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a viral infection by administering the compound of claim 1.
Dependent claims
Dependent claims further specify particular substitutions, dosage forms, and treatment regimens, narrowing the scope but adding detail to the patent protections.
Claim breadth considerations
The claims are relatively broad within the structural framework, covering not only the specific compound but also analogs with minor modifications that retain the core structure. This breadth aims to block similar compounds with slight variations from entering the market.
What is the current patent landscape surrounding US 6,143,775?
Patent family and related patents
The patent belongs to a family of patents extending into Europe, Australia, and Japan, with filings primarily aimed at global protection of the core invention.
Key competitors and patent overlap
Numerous patents exist in the antiviral space, many claiming related heterocyclic compounds. Notable overlap occurs with patents owned by major pharmaceutical firms targeting similar molecular scaffolds, such as Gilead Sciences and Roche.
Patent expiration status
The patent has a 20-year term from the filing date, expiring in August 2019. Nonetheless, continuation and divisional applications have extended protection in certain jurisdictions through patent term adjustments and patent term extensions, notably in the U.S.
Recent patent filings
Recent filings aim at specific analogs or related therapeutic indications, often with narrower claims. These seek to carve out niches around the original broad patent or to update protection as new data becomes available.
Litigation and licensing activity
Limited litigation records exist concerning this patent. However, licensing agreements show active commercialization efforts, especially in antiviral therapeutics, with some disputes over patent validity and scope in specific jurisdictions.
Closing summary
US Patent 6,143,775 solidifies exclusive rights to a class of heterocyclic compounds, their compositions, and therapeutic methods. Its claims are broad within the structural parameters, covering derivatives and analogs, which influences the competitive landscape. The patent’s expiration and the activity around related patents shape ongoing innovation and IP strategies in antiviral drug development.
Key Takeaways
- The patent claims cover a specific pyrimidine-based compound, its formulations, and treatment methods.
- The scope includes broad classes of derivatives, with claims at risk of being challenged for obviousness or lack of novelty.
- The patent family extends protections internationally but expired in the U.S. in 2019.
- Competition involves numerous patents with overlapping molecular scaffolds, often with narrower claims.
- Licensing activities suggest commercial interest despite the patent’s age and expiration.
FAQs
1. Can the patent claims be challenged for invalidity?
Yes. Arguments against validity could include lack of novelty, obviousness based on prior art, or insufficient disclosure. The broad scope makes it vulnerable to such challenges.
2. What are strategic considerations for competitors?
Competitors may focus on designing analogs outside the patent claims or filing narrow patents around specific derivatives to bypass protection.
3. How does patent expiration impact drug development?
Expiration opens the market for generics and biosimilars, enabling cheaper versions of the drug and increased competition.
4. Are there active patent extensions or related patents?
Yes. Ongoing patent applications and extensions maintain some protection, particularly for specific formulations or uses.
5. What are the implications for licensing and commercialization?
Existing licenses indicate ongoing commercialization efforts. Patent expiration reduces licensing value but may lead to generic manufacturing.
References
- U.S. Patent and Trademark Office. (2000). Patent No. 6,143,775. https://patents.google.com/patent/US6143775
- WIPO. (n.d.). Patent family data. https://www.wipo.int
- European Patent Office. (n.d.). Global patent family status. https://patentscope.wipo.int/search/en/detail.jsf
- M. Johnson, et al. (2020). Patent landscape analysis in antiviral compounds. Journal of Intellectual Property Rights, 25(4), 245-258.
